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R E V I EW
Growth in CHARGE syndrome: optimizing care
with a multidisciplinary approach
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Abstract: CHARGE (Coloboma of the eye, Heart defects, Atresia of the choanae, Retardation
of growth and/or development, Genital hypoplasia, Ear anomalies including hearing loss)
syndrome is a rare syndrome with an incidence of approximately 1:15,000 newborns. It is
caused by pathogenic variants in the CHD7 gene and clinically characterized by a wide range
of anomalies with variable expression. Growth retardation affects 60–72% of children with
CHARGE syndrome, making it one of the most prominent medical issues in the syndrome.
Growth retardation in CHARGE syndrome is thought to be multifactorial and can be inﬂu-
enced by almost all co-morbidities, requiring a multidisciplinary approach to the different
medical problems. In this systematic review, we describe what is currently known about
growth in CHARGE syndrome and how it is inﬂuenced by commonly seen clinical problems
including feeding difﬁculties, hypogonadotropic hypogonadism and growth hormone deﬁ-
ciency. Furthermore, we provide recommendations for a multidisciplinary approach.
Keywords: CHARGE syndrome, growth, short stature, multidisciplinary, hypogonadotropic
hypogonadism
Introduction
CHARGE syndrome (OMIM 214800) is a rare disorder with an estimated incidence of
1 in 15,000 to 1 in 17,000 live births.1 It is characterized by a wide spectrum of
anomalies that vary among patients. In 1981, Pagon introduced the acronym CHARGE
based on some of the most prevalent anomalies in the syndrome: Coloboma of the eye,
Heart defects, Atresia of the choanae, Retardation of growth and/or development,
Genital hypoplasia and Ear and hearing abnormalities.2 CHARGE syndrome can be
clinically diagnosed by using the Blake or Verloes criteria.3,4
In 2004, variants in the CHD7 gene (OMIM 608892) were identiﬁed to be
responsible for the CHARGE phenotype.5 Since then, more than 1000 variants in
CHD7 have been identiﬁed, and a CHD7 variant is found in 83–95% of patients
fulﬁlling Blake or Verloes’ diagnostic criteria.6,7 Next-generation sequencing tech-
niques have led to the identiﬁcation of an increased number of CHD7 gene variants
and to increased detection of these variants in patients with a mild phenotype. The
majority of CHD7 gene variants are nonsense or frameshift mutations, while
missense and splice site mutations have been detected in a minority of cases, and
deletions, duplications and chromosomal rearrangements are rare.1
CHARGE syndrome is a clinically variable syndrome, and there is no clear correla-
tion between genotype and phenotype when focusing on individual cases. However,
patients with a missense mutation generally have a milder phenotype, and missense
mutations are more frequently found in patients with Kallmann syndrome.8–10
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CHARGE syndrome is thought to be caused by a loss of
function of CHD7 and has an autosomal dominant inheri-
tance pattern. Most cases are caused by de novo mutations,
although some familiar cases have been reported.1,11,12
In 2016, new clinical criteria were proposed that consist
of the revised Blake criteria with the addition of a pathogenic
variant in the CHD7 gene as a major criterion.13
Growth retardation and hypogonadotropic hypogonadism
(HH) are important aspects of CHARGE syndrome in both
boys and girls. Short stature is reported in 60–72% of patients
with CHARGE syndrome, although the underlying cause is
often not well-documented.14–16 HH is also highly prevalent,
and 60–88% of patients with CHARGE syndrome do not
achieve puberty spontaneously. Nonetheless, there are no syn-
drome-speciﬁc guidelines on how to induce puberty in this
group of patients who frequently exhibit challenging behavior
and thereforemay respond differently to hormone replacement
therapy.7,16–19
A number of studies have now been published that
describe aspects of growth and puberty in CHARGE syn-
drome. The aim of this review is to summarize what is
currently known about growth in CHARGE syndrome in
order to make recommendations for the multidisciplinary
approach and identify what future studies are needed to
develop evidence-based guidelines for growth and puberty
surveillance in CHARGE syndrome.
Methods
For this systematic review, we conducted a literature search on
growth and puberty in CHARGE syndrome in PubMED using
MeSH terms and in Embase using Emtree terms. We also
searched on title and abstract based on keywords related to
growth and puberty and included publications regarding
CHD7 and Kallmann syndrome because HH is also a feature
of Kallmann syndrome and mutations in the CHD7 gene may
be found in these patients.20 Our search terms and selection
process are described in Figure 1. We excluded all duplicate
records and those that were not in English and selected possi-
bly relevant records on title and abstract. The ﬁnal selection
was made after reading the complete publication (DD, GB).
The references of the selected articles were checked for any
relevant articles that might have been missed.
Results
Growth in CHARGE syndrome
Of the studies we found, 22 speciﬁcally mentioned growth
and 18 of these presented growth data in percentiles or SD
values in relation to a reference population. These results are
summarized in Table 1. Below, we review the current
knowledge about growth in the context of different phases
of life.
Fetal growth
In a cohort of 119 children with CHARGE syndrome, the
mean gestational age at birth was 36.6±2.2 weeks.7 In
another small cohort, 16 out of 17 children were born at
term.21 Birth weight and length were generally normal or
slightly reduced when compared to a reference
population.7,18,21–28 However, a small proportion of chil-
dren with CHARGE syndrome are small for their gesta-
tional age.21–23,27 According to Legendre and Pinto, this is
true for 26–34% of children with CHARGE syndrome.7,18
In another study by Legendre et al that described the
characteristics of 40 deceased fetuses with CHARGE syn-
drome, no intra-uterine growth retardation was found.29
This is remarkable considering that this group probably
represents the more severely affected spectrum of
CHARGE syndrome. Thus, the largest decrease in growth
velocity happens the ﬁrst period after birth.
Growth from 0–3 years
All the published studies we found showed a sudden decrease
in growth rate from early infancy onwards.16,18,21,24–28,30 In a
study of 19 German children aged 0–6 years, a sudden
decrease in growth rate and body length was documented
from as early as 4 weeks of agewhen compared to a reference
population.26 Some authors have described catch-up growth
in pre-school years,24,27 while others have described persis-
tently delayed growth with a height between −2.36 and −5.6
SD and no catch-up growth.16,18,21,26,30 In addition to short
stature, weight is also frequently below average and BMI is
low.26
Growth from 3–12 years
During the early school years, short stature persists in children
with CHARGE syndrome, with an average height between −2
to −3 SD below the reference population.16,18,21,23,26,28,30 In
these years, the risk of developing scoliosis should warrant
attention (see section Factors contributing to growth
retardation).
Growth from 12–18 years and later: growth from
12–18 years and later
During the adolescent years, height remains signiﬁcantly
below average,16,21,25 and the majority of children with
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CHARGE syndrome have absent or delayed puberty due
to HH.17 These children will not undergo a pubertal
growth spurt unless treated with hormone replacement
therapy (HH is discussed in section Factors contributing
to growth retardation).
Weight tends to increase in adolescence and adulthood,
which poses a risk for the development of obesity, and there is
some anecdotal evidence that older individuals with
CHARGE syndrome are at risk for developing obesity.14,28
However, other studies are less conclusive, indicating that
weight is still below average.7,16,21,25,31 In a study of 30
adolescents and adults with CHARGE syndrome, Forward et
al found that 74% had normal weight, 15% were underweight
and 11% were overweight.31
Factors contributing to growth retardation
There are many different characteristics in CHARGE syn-
drome that may negatively inﬂuence growth, with feeding
difﬁculties, cardiac malformations, frequent hospitalization
and multiple surgeries being particularly important. In addi-
tion, endocrinological problems such as growth hormone
deﬁciency, HH and hypothyroidism can negatively inﬂuence
growth. Below we review the most common factors that may
inﬂuence growth in CHARGE syndrome per age group.
0–3 years of age
Feeding difﬁculties
The prevalence of feeding difﬁculties in CHARGE syn-
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Publications including growth data (n=18)
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Figure 1 Flow chart of publication selection. Entry terms: CHARGE syndrome, CHARGE association, Hall Hittner syndrome, Hall Hittner association, growth, body size,
weight, height, body mass, BMI, length, birth weight, head circumference, short stature, birth size, morphometry, anthropometry, puberty, hypogonadism, Kallmann,
adolescent and adolescence. MeSH terms for PubMED search: CHARGE syndrome, Body weights and measures, growth and development, puberty, delayed puberty and
hypogonadism. Emtree terms for Embase search: syndrome CHARGE, morphometry and growth, development and aging.
Abbreviations: CHARGE, coloboma of the eye, heart defects, atresia of the choanae, retardation of growth and/or development, genital hypoplasia, ear anomalies including
hearing loss. BMI, body mass index.
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individuals with CHARGE syndrome have been tube fed
at some point in their life.32 These numbers indicate that
feeding difﬁculties are a very important issue in CHARGE
syndrome. The decrease in growth rate in early infancy
and the slow weight gain during the largest part of child-
hood strongly suggest that these feeding difﬁculties are an
important factor in growth retardation.
While feeding difﬁculties can occur at any age, they
probably inﬂuence growth most in early childhood. There
are many different reasons why feeding is at risk in
CHARGE syndrome. These include problems with chew-
ing, sucking and swallowing. These issues are mainly due
to cranial nerve dysfunction, but they are also inﬂuenced
by hypotonia and anatomical variations of the facio-oral
region, such as atresia of choanae and cleft lip and/or
palate. A vascular ring can also impede food passing
down through the esophagus. In addition, sensory pro-
blems such as hypersensitivity and anosmia can make
eating or drinking uncomfortable or unpleasant. Aberrant
feeding behavior, like pocketing food or unusual chewing
or swallowing patterns are common in CHARGE
syndrome.32–35
In addition to problems with ingestion, gastro-intestinal
problems can also have a negative inﬂuence on feeding.
Gastro-esophageal reﬂux is a common problem in
CHARGE syndrome, and abdominal migraine and consti-
pation can cause abdominal pain and reduced appetite.35
Critical illness, multiple surgeries and hospital
admissions
Children with CHARGE syndrome often require many
medical interventions and hospitalizations, particularly at a
young age.36 Research among children from the general
population in the pediatric intensive care unit and neonatal
intensive care unit has shown that these children, especially
infants, have an increased risk of malnourishment and
growth retardation that is probably caused by a combination
of increased metabolic state and feeding difﬁculties.37,38
Cardiovascular malformations
Cardiovascular malformations are common in CHARGE
syndrome, with 65–92% of patients having a cardiovascular
malformation. Many different types of malformations can
occur, with the most prevalent being conotruncal defects,
septal defects and atrioventricular septal defects.6,7,39 As
discussed above, a vascular ring can cause swallowing
problems if it occludes the esophagus.33 Cardiovascular
malformations are also associated with malnutrition and
failure to thrive, probably due to a combination of a hyper-
metabolic state, inadequate caloric intake, feeding difﬁcul-
ties and gastro-intestinal problems.40 Of note, poor growth
in children with cardiovascular malformations has been
associated with poorer physical and neurodevelopmental
outcomes.40,41
4–12 years of age
Skeletal abnormalities
Scoliosis is a common problem in CHARGE syndrome
due to decreased muscle tone. In a survey of 31 older
patients with CHARGE syndrome, 19 were reported to
have scoliosis with variable severity, and the mean age at
which scoliosis was diagnosed was 6.25 years.14 The pre-
valence of scoliosis was also high in another cohort of
older individuals with CHARGE syndrome, where
Forward et al reported a prevalence of 50% in a cohort
of individuals aged 13–34 years.31 Scoliosis can nega-
tively inﬂuence height and usually deteriorates with age.
Therefore, when considering growth hormone treatment, a
physical examination should be conducted with special
attention paid to the presence of scoliosis because of the
risk of deterioration with increased growth rate.
Growth hormone deﬁciency, hypothyroidism and
hypoparathyroidism
Because most individuals with CHARGE syndrome have
short stature and HH, other pituitary functions in
CHARGE syndrome have been frequently studied.
Combined pituitary dysfunction is uncommon in
CHARGE syndrome. Some authors have reported
hypothyroidism among patients with CHARGE syndrome
with a prevalence of 12–18%.16,21,23 However, Pinto et al
did not report hypothyroidism among 26 patients tested for
abnormal levels of TSH and free T4.18 Incidental cases of
hypoparathyroidism have been found in patients with typi-
cal and atypical CHARGE syndrome.7,16,42 Given their
low prevalence, the risk of poor growth due to hypothyr-
oidism or hypoparathyroidism in CHARGE syndrome is
probably small.
Growth hormone deﬁciency is more common in
CHARGE syndrome, being reported with a frequency of
12–34% in several studies.7,15,18,23 Growth hormone ther-
apy may be a safe and effective way to increase growth in
patients with CHARGE syndrome suffering from growth
hormone deﬁciency, although no randomized controlled
trials are available. In a cohort study of 16 patients with
CHARGE syndrome who were registered in the Pﬁzer
Dovepress Dijk et al
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international growth database for patients treated with
growth hormone, growth velocity increased after growth
hormone supplementation and adverse events were gener-
ally mild, although one patient with kyphoscoliosis was
reported.43 Therefore, when considering growth hormone
treatment, a physical examination should be conducted
with special attention to the possible presence of scoliosis
due to its increased prevalence in CHARGE syndrome and




Delayed or absent puberty due to HH is common in
CHARGE syndrome. The prevalence of HH is estimated
to be between 60% and 88%, with HH being more com-
mon in boys. In boys, cryptorchidism and micropenis may
be signs of HH, while girls usually have normally devel-
oped external genitalia. However, in a minority of cases,
girls present with hypoplastic labia at birth. Other geni-
tourinary malformations related to HH in girls with
CHARGE syndrome are rare.6,7,16–18,44
HH can be diagnosed in the ﬁrst 6 months of life or at
pubertal age by the detection of low blood levels of lutei-
nising hormone and follicle stimulating hormone, together
with low levels of testosterone in boys and estradiol in
girls. Due to a strong correlation between olfactory func-
tion and HH in CHARGE syndrome, the presence of
anosmia is a strong indicator of HH.17,18 This co-occur-
rence of anosmia and HH also occurs in Kallmann syn-
drome, which suggests an overlap between both
syndromes. Several studies have shown that approximately
6% of patients previously diagnosed with Kallmann syn-
drome have a CHD7 gene mutation, and most of these
patients appeared to have more CHARGE syndrome char-
acteristics after close examination.20,45–47
HH can be treated by hormone replacement therapy,
either with testosterone or human chorionic gonadotropin
(which stimulates the production of testosterone in the
testis) in boys and estrogens in girls.48 Currently, there is
no evidence-based data on what is the preferred therapy
for male HH in CHARGE syndrome.
HH may contribute to a short stature because patients
with HH lack a pubertal growth spurt. When hormone
replacement therapy is not started, growth will slowly
continue through adolescent years due to delayed epiphy-
seal closure.49 This may lead to a taller ﬁnal height, but
usually results in characteristic body proportions with
relatively long limbs and a short trunk.
Another important complication of delayed puberty is
osteoporosis. The risk for osteoporosis is probably further
increased in patients with CHARGE syndrome due to
feeding difﬁculties and a reduced level of physical
activity.31 Thus, in addition to inducing the development
of secondary sexual physical characteristics, hormone
replacement therapy may be important to both prevent
osteoporosis and improve growth.
Recommendations for multidisciplinary
care
The need for a multidisciplinary approach to the medical
problems in children with CHARGE syndrome was already
being discussed in 1990 when Blake et al studied 50
patients with CHARGE association, the majority of whom
underwent at least one major surgical intervention.50 The
authors concluded that outcome could be improved by
collaboration between specialist surgical teams and sug-
gested that a pediatric Ear Nose Throat (ENT)-specialist
and a general or community pediatrician would be the
most appropriate coordinators of the long-term multidisci-
plinary management of these patients. Since then, only a
few articles have been published on the multidisciplinary
care of children with CHARGE syndrome,51 which is
remarkable given that the expanding phenotype of
CHARGE syndrome44 has led to an increased number of
medical disciplines becoming involved in the care of chil-
dren with CHARGE syndrome.
The healthcare transition from pediatrics into adult
care systems requires special attention. In the last dec-
ades, there has been an increased awareness of the impor-
tance of healthcare transition into adulthood of patients
with pediatric-onset conditions.52 However, effective
transition remains challenging, particularly for patients
with rare and complex conditions.53 In addition, many
studies have shown that people with intellectual disabil-
ities experience health disparities, partly due to limited
access to care.54,55
Inefﬁcient and siloed systems, lack of resources, lack
of communication and collaboration between profes-
sionals, and a lack of knowledge among adult health care
professionals about pediatric-onset conditions, rare dis-
eases and intellectual disability have been recognized as
barriers to effective transition of care and targets for
improvement of transition.56
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There are many different ways to organize healthcare
transition. A review by Gabriel et al showed that different
types of transition strategies have proved to be successful
with regard to population health, consumer experience and
utilization of care as long as they provide a systematic
approach.57 Thus, depending on the local situation, effec-
tive health care transition can be modelled in several ways.
However, the following aspects should be incorporated:
the transition should be started in a timely manner, it
should involve a broad view on care (such as attention to
issues like fertility and legal representation), it should
involve extensive communication between the pediatric
team and the adult team and there should be a coordinating
care provider. The American Academy of Pediatrics
advises to start planning healthcare transition from 12–
14 years of age.52 In CHARGE syndrome, multidisciplin-
ary CHARGE clinics can play an important role in this
transition, either by providing adult care themselves or by
educating local healthcare providers about CHARGE syn-
drome and patient-speciﬁc topics. During childhood, a
pediatrician is usually the coordinating health care provi-
der. In adulthood, this role should be transferred to a
physician working with adults, preferably someone with
expertise on complex disorders.58,59
Growth monitoring is considered part of standard
pediatric care. It is important for identifying children
who are at risk of undernutrition or have a medical condi-
tion that affects growth, and appears to be cost-effective.60
There is some evidence that retarded growth in early
childhood is associated with worse neurodevelopmental
outcomes and might also negatively inﬂuence adult health
parameters. However, this research is complicated by the
presence of confounders.61,62 Research among children
with congenital heart disease showed that low weight for
age was associated with prolonged hospitalization, a
higher rate of infections and a higher mortality rate after
cardiac surgery.40,41 The largest decrease in growth velo-
city in CHARGE can be seen in the ﬁrst years of life. This
decrease, which occurs during the most critical period of
life from a medical perspective, suggests that at least part
of this early growth retardation is inﬂuenced by chronic
illness, multiple surgeries and feeding difﬁculties. This
provides a challenge for professionals: How can we limit
the number of hospital visits and medical procedures and
optimize nutritional status? However, there are other
health problems common in CHARGE syndrome that
can also inﬂuence growth. Given the complex nature of
the syndrome and the co-occurrence of these problems, a
multi-disciplinary approach is essential. In Table 2 we
summarize the most important problems and which pro-
fessionals we suggest should be consulted.
Growth monitoring and health follow-up is preferably
done by a pediatrician who has regular contact with the
parents and who can decide when consultation with other
professionals is necessary. A useful guideline and checklist
was provided by Trider et al and supplemented with radi-
ological guidelines by de Geus et al.63,64 The discussion
below provides more information with regard to speciﬁc
growth-related issues.
Feeding difﬁculties
At birth, children with CHARGE syndrome should be
checked for choanal atresia by an ENT-specialist.
Orofacial anomalies that require surgery, such as choanal
atresia and cleft lip and/or palate, can be treated by an
ENT specialist or plastic surgeon.63 When feeding difﬁ-
culties are present, a speech therapist should be consulted
for feeding analysis.63 Based on the nature of the pro-
blems, other professionals can be involved (see Table 2).
Blake and Hudson have written a useful review of feeding
difﬁculties in CHARGE syndrome that includes practical
advice for speciﬁc problems.33
Chronic or critical illness
At birth, all children with CHARGE syndrome should be
screened for cardiovascular malformations, including a
vascular ring, by means of a cardiac ultrasound and chest
X-ray.63 When cardiovascular malformations are present,
the child has to be referred to a pediatric cardiologist. The
number of hospital admissions and anesthesias should be
limited as much as possible. While in hospital, and before
and after surgical intervention, extra attention should be
paid to possible feeding difﬁculties and undernutrition. A
dietician and speech therapist can help to improve feeding
and nutritional status.40
Endocrine issues
Given the possibility of diagnosing HH during the so-
called mini-puberty of infancy, a pediatric endocrinologist
should be consulted in the ﬁrst weeks or months of life and
then again when the patient is reaching pubertal age or
when growth hormone deﬁciency is suspected. Evaluation
for hypothyroidism and hypoparathyroidism is only neces-
sary if there are clinical signs or symptoms.
Dovepress Dijk et al
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Conclusion
Growth retardation and short stature are present in the
majority of individuals with CHARGE syndrome. Height
and weight remain low in CHARGE children in all age
groups, and adults typically have short stature. However,
the largest decrease in growth velocity occurs in the ﬁrst
years of life. Given the broad spectrum of condition-related
factors that might inﬂuence growth retardation, this com-
plex problem requires a multidisciplinary approach towards
diagnostics and treatment.
Strengths and limitations of this study and
recommendations for further research
In this review we systematically searched for previously
published growth data to present the most extensive over-
view of growth data published thus far. However, because
of the different ways of reporting growth data in the
different studies and the low patient numbers per study,
it was only possible to get a general overview of growth in
CHARGE syndrome. Moreover, interpretation of body
weight data is difﬁcult because of the generally short
stature. To be truly applicable in daily clinical practice,
systematic collection of growth data and construction of
CHARGE-syndrome-speciﬁc growth charts is necessary.
We have also described many factors that can negatively
inﬂuence growth in CHARGE syndrome. However, no stu-
dies in children with CHARGE syndrome have proven that
there is a statistically signiﬁcant correlation between these
conditions and growth retardation. The recommendations we
make regarding interventions to improve care are therefore
based on expert opinions. An extensive growth study with an
analysis of the factors that inﬂuence growth would allow us
to gain more insight into growth-related problems in
CHARGE syndrome. For example, it would be interesting
to know whether there is an intrinsic CHD7 gene haploin-
sufﬁciency-effect on growth. Of the studies in this review,
only Aramaki et al and Shoji et al described patients in
sufﬁcient detail to make it possible to compare their growth
to their genotype.16,21 Dauber et al also presents one patient
with a missense mutation and describes the growth charac-
teristics of this patient.25
Aramaki and Shoji described 12 patients with a non-
sense mutation, 13 patients with a frameshift mutation, 6
patients with a splice site mutation and 3 patients with a
deletion.16,21 In this small cohort, we could not ﬁnd a
correlation between these different mutation types and
growth. Due to the fact that we only had growth data for
one patient with a missense mutation, we could not look
into the effect of truncating vs non-truncating mutations on
growth. In addition, some studies describe familial cases
with CHARGE syndrome or cases of unrelated patients
with identical CHD7 gene variants. The effect of identical
gene variants on growth appears to be variable, which is in
line with the wide variation in other characteristics of
CHARGE syndrome observed in patients with identical
gene mutations.6,7,11,12,65–67
Finally, knowledge about the risks and beneﬁts of
growth hormone therapy and hormone replacement ther-
apy for HH in CHARGE syndrome remains limited. More
research is needed to be able to make an evidence-based
guideline on those therapies.
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